VIVEbiotech featured in Drug Discovery News for its advances in in vivo lentiviral vector delivery
DDN highlights the growing importance of in vivo gene therapy and includes expert insights from Natalia Elizalde, Chief Business Officer at VIVEbiotech.
We are pleased to announce that VIVEbiotech has been featured in a new Drug Discovery News (DDN) publication. The article, titled “The future of gene therapy depends on mastering in vivo delivery,” explores how in vivo approaches are reshaping the landscape of cell and gene therapy.
The article includes insights from various industry leaders, including Natalia Elizalde Urdiain, Chief Business Officer at VIVEbiotech, who was interviewed during the Advanced Therapies UK congress organized by Terrapinn. In her contribution, Natalia discusses our progress in advancing lentiviral vector technologies for in vivo applications. She highlights how our approach — combining highly productive vector manufacturing and engineered pseudotypes — is supporting the growing number of in vivo CAR T programs worldwide.
With 14 ongoing in vivo programs, VIVEbiotech continues to strengthen its role as a key partner for next‑generation gene therapy platforms and developers globally.
For organizations exploring in vivo lentiviral‑vector delivery and seeking a partner with deep expertise in vector engineering and scalable manufacturing, the VIVEbiotech team is ready to collaborate.